Survodutide (BI 456906) is a GLP-1R/GCGR dual agonist developed by Boehringer Ingelheim, with outcomes of a phase 2 trial in MASLD and a phase 1 trial in cirrhosis published almost simultaneously with tirzepatide
Proprietary Research Compound Profile Chemical Specifications Research unit: 1 capsule Units per container: 30 BPC-157 Arginate + PEA (CAS 137525-51-0 / CAS 544-31-0) C62H98N16O22 MW 1419.53 g/mol (BPC-157 Arginate) / C16H33NO2 MW 299.49 g/mol (PEA) Purity 98% HPLC 3000 mcg Ac-SDKP Ac-SDKP CAS 116503-58-1 C19H30N4O7 MW 442.49 g/mol Purity 98% HPLC 1500 mcg Not for human consumption
Leaky gut and the liver: a role for bacterial translocation in nonalcoholic steatohepatitis
In addition, L-carnitine caused higher glycogen deposition in the fasting state, and increased and decreased the mRNA expressions of gluconeogenesis-related and glycolysis-related genes, respectively
In mammalian cells, ER stress leads to an integrated stress response involving the related transmembrane kinases Ire1, Ire1 and PKRlike ER kinase (PERK), and the transmembrane activating transcription factor 6 (ATF6) (Zhang & Kaufman, 2004)
PMID: 37602204
,aspect=ignore)
